Primary cutaneous anaplastic large-cell lymphoma: Complete remission for 13 years after denileukin diftitox
نویسندگان
چکیده
CLS: capillary leak syndrome CR: complete remission CTCL: cutaneous T-cell lymphoma DD: denileukin diftitox pcALCL: primary cutaneous anaplastic large-cell lymphoma Treg: T-regulatory cell INTRODUCTION Denileukin diftitox (DD) is a recombinant fusion protein that consists of the interleukin-2 molecule conjugated to the catalytic domain of diphtheria toxin. It targets cells expressing the high-affinity interleukin-2 receptor, such as activated T lymphocytes in cutaneous T-cell lymphoma (CTCL). After binding to the interleukin-2 receptor, DD undergoes endocytosis followed by release of diphtheria toxin, which inhibits protein synthesis and induces subsequent cell apoptosis. DD was approved by the US Food and Drug Administration in 1999 for the treatment of persistent or recurrent CTCL. However, the pivotal trial leading to the drug’s approval only included patients with mycosis fungoides or S ezary syndrome. Although its clinical activity in other forms of CTCL remains unclear, DD may be useful for primary cutaneous anaplastic large-cell lymphoma (pcALCL). We report the case of a patient with recurrent pcALCL who has maintained complete remission (CR) for 13 years after treatment with DD.
منابع مشابه
Denileukin Diftitox (Ontak) as Maintenance Therapy for Peripheral T-Cell Lymphomas: Three Cases with Sustained Remission
Peripheral T-cell lymphomas (PTCL) are rare but markedly aggressive forms of non-Hodgkin's lymphoma (NHL). They carry a poor prognosis, with current therapeutic approach being generally ineffective. The most employed first-line treatment is CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), which still results in high rates of relapses. Denileukin diftitox is a fusion protein co...
متن کاملAdvanced-Stage Primary Cutaneous T-Cell Lymphoma Treated with Bexarotene and Denileukin Diftitox
Advanced-stage primary cutaneous T-cell lymphoma has an unfavorable prognosis and low survival rates. Aggressive treatment with chemotherapy is not curative and causes considerable side effects. The combination of bexarotene and denileukin diftitox is associated with an acceptable safety profile and a likely synergistic effect because bexarotene is capable of modulating expression of IL-2 recep...
متن کاملCLINICAL FEATURES AND TREATMENT OUTCOME IN 26 CASES WITH Ki-l (CD30) POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA
In order to present the clinical features and outcome of patients with Ki-l positive lymphoma and also the role of treatment modalities in this type of malignant disease, twenty-six patients with peripheral lymphadenopathy and a biopsyproven diagnosis ofKi-l positive lymphoma referring to the Radiation Oncology Department during a seven year period were treated with chemotherapy and radioth...
متن کاملA phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.
Denileukin diftitox, a genetically engineered fusion protein combining the enzymatically active domains of diphtheria toxin and the full-length sequence for interleukin-2 (IL-2), efficiently targets lymphoma cells expressing the high-affinity IL-2 receptor (IL-2R) consisting of the alpha/p55/CD25, beta/p75/CD122, and gamma/p64/CD132 chains. In vitro studies demonstrated that the retinoid X rece...
متن کامل